Plain-English translation of NCT06403878 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination treatment called nab-paclitaxel, , and given before surgery for older patients with advanced esophageal squamous cell carcinoma. The trial combines chemotherapy (two drugs) with immunotherapy (one drug) to shrink the cancer before surgery. Researchers want to understand if this approach works well and is safe in elderly patients, who are often left out of cancer treatment studies.
Most previous cancer trials have excluded patients aged 70 and older, even though many elderly people develop esophageal cancer. Older patients often have other health conditions and may not tolerate standard treatments well. This trial aims to find out if this medication combination is an effective and safe option specifically designed for this older population.
You likely qualify if…
You likely don't qualify if…
You will receive the three-drug combination treatment as an outpatient over several weeks before your scheduled surgery. During this time, you will have regular clinic visits for treatment doses, blood tests to monitor your health and side effects, and imaging scans to see how the cancer is responding. After completing the medication treatment, you will proceed to surgery to remove the cancer. The study team will continue to follow up with you after surgery to track your recovery and long-term outcomes.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China